PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: Pipeline portfolio PART 06: Market landscape • Market overview • Market size and forecast • Five forces analysis PART 07: Market segmentation by disease type PART 08: Global CLL therapeutics market • Market overview • Total addressable market for global CLL therapeutics • Vendors in the market PART 09: Global ALL therapeutics market • Market overview • Vendors in the market PART 10: Global AML therapeutics market • Market overview • Vendors in the market PART 11: Global CML therapeutics market • Market overview • Vendors in the market PART 12: Geographical segmentation • Global leukemia therapeutics market by geography 2015-2020 • Leukemia therapeutics market in Americas • Leukemia therapeutics market in EMEA • Leukemia therapeutics market in APAC PART 13: Market drivers • Special regulatory designations for drugs • Technological advances in the monitoring of leukemia • Application for expanded indication approvals PART 14: Impact of drivers PART 15: Market challenges • Complicated disease prognosis • Financial and infrastructural constraints • Limitations associated with current therapeutic options • Delay in diagnosis PART 16: Impact of drivers and challenges PART 17: Market trends • Rise in the development of combination therapies • Patient assistance programs • Focus on the identification of targets for the development of new therapies PART 18: Vendor landscape • Competitive scenario • Other prominent vendors PART 19: Key vendor analysis • F. Hoffmann-La Roche • Novartis • Bristol-Myers Squibb • AbbVie • Teva Pharmaceuticals PART 20: Appendix • List of abbreviations PART 21: Explore Technavio

F. Hoffmann-La Roche, Novartis, Bristol-Myers Squibb, AbbVie, Teva Pharmaceuticals, Altor BioScience, Amgen, ARIAD Pharmaceuticals, Arno Therapeutics, Astex Pharmaceuticals, AstraZeneca, Baxter Healthcare, Bayer HealthCare, Bellicum Pharmaceuticals, Biogen, Boehringer Ingelheim, BioLineRx, Boston Biomedical, Celator Pharmaceuticals, Celgene, CTI BioPharma, Chroma Therapeutics, Chugai Pharmaceutical, Cyclacel Pharmaceuticals, Daiichi Sankyo, Eisai, Emergent BioSolutions, Erytech Pharma, Fate Therapeutics, Genzyme, Gilead Sciences, GlaxoSmithKline, iDD biotech, Immune Pharmaceuticals, Immunomedics, Infinity Pharmaceuticals, Innate Pharma, Jazz Pharmaceuticals, Juno Therapeutics, Karyopharm Therapeutics, Ligand Pharmaceuticals, MEDA Pharmaceuticals, MedImmune, Merck, Midas Pharma, Molecular Templates, MorphoSys, Nippon Shinyaku, Novo Nordisk, Onconova Therapeutics, Ono Pharmaceuticals, Orphan Europe, Otsuka, Pfizer, Portola Pharmaceuticals, Regeneron Pharmaceuticals, Sanofi, Sigma-Tau Pharmaceuticals, Stemline Therapeutics, Sunesis Pharmaceuticals, TG Therapeutics, TheraMAB, Tolero Pharmaceuticals, XEME Biopharma, Xencor, and ZIOPHARM Oncology.